Biology
The Emergence of Synthetic Biology and Its Governance Gaps
Quick fact
Synthetic biology now allows DNA sequences to be designed and ordered online for a few hundred dollars, and the number of organizations with the equipment to construct viruses and bacteria has grown from a handful of research labs to thousands worldwide, yet no comprehensive international treaty specifically regulates synthetic organisms.
Why this is interesting
Imagine being able to program a living cell like you program a computer—designing bacteria to manufacture medicine or even fuel. Now imagine that these creations could be made by nearly anyone, but no single set of rules governs them. What happens when innovation outpaces oversight?
Read the full explanation
Understanding The Emergence of Synthetic Biology and Its Governance Gaps
Synthetic biology is a field that applies engineering principles to biology: it aims to standardize biological parts, design new genetic circuits, and even construct entire genomes. The goal is to make biology predictable and programmable, just like writing software for a machine. However, this capability grows faster than our systems for governing it. Governance typically refers to the set of rules, regulations, and practices that ensure a technology is developed and used safely and ethically. In many countries, existing regulations were created during the era of genetic engineering, focusing on contained laboratory use and GMO releases. But synthetic biology goes beyond traditional genetic modification: it can involve creating organisms with no natural counterpart, or using synthetic DNA that may be hard to detect. These differences expose 'governance gaps'—areas where regulations do not clearly apply, or where oversight is split among multiple agencies, leaving some activities unregulated or overseen only through voluntary guidelines.
A deeper explanation
The core mechanism behind the governance gap is the 'pace' and 'place' mismatch between innovation and regulation. Traditional regulation is slow, evidence-based, and built in response to well-understood risks. Synthetic biology, however, advances rapidly, often with unpredictable outcomes, and the technology is highly accessible, enabling many different actors—including hobbyists and small companies—to participate with minimal oversight. This creates three specific gaps: (1) 'regulatory gaps' where existing rules do not cover new applications or organisms, (2) 'jurisdictional gaps' where responsibility is scattered across different agencies (e.g., environment, health, agriculture) without a central authority, and (3) 'international gaps', where national regulations vary widely, allowing activities that are restricted in one country to move to another with weaker controls. Moreover, the convergence of biology with computing and automation multiplies the challenge: digital DNA sequences can be exchanged over the internet, and the physical DNA can be synthesized from those codes, making oversight of a physical trade also require oversight of digital information. The precautionary principle, which would require proof of safety before release, is often in tension with the desire to foster innovation. Understanding these gaps matters because synthetic biology holds tremendous promise for medicine, materials, agriculture, and environmental cleanup—but also raises novel risks, from accidental release to deliberate misuse. A robust governance framework would require international cooperation, adaptive regulations, and mechanisms to ensure safety and ethics at every stage.